Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Trade Show, Webcast

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences


Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.

Wells Fargo Virtual Healthcare Conference (Fireside Chat)

H.C. Wainwright 23rd Annual Global Investment Conference (Presentation)

Baird Global Healthcare Conference (Fireside Chat)

Vaccine Summit 2021 (Presentation)

TIDES Boston (Presentation)

Cantor Global Healthcare Conference (Presentation)

Links will be available under the Investor Relations/Events section of Arcturus' website.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARRtm mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (230 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.


These press releases may also interest you

at 15:25
New LegalShield Data: Consumer Stress in Swing States Currently Suggests a Democratic Win in November
LegalShield's March Consumer Stress Legal Index (CSLI) is starting to exhibit a pattern seen in the past five presidential election cycles: The relationship of swing-state stress as measured in LegalShield's CSLI relative to the national average...

at 15:05
9-Time GRAMMY® Winner Sheryl Crow and Sens. John Cornyn and Amy Klobuchar to Be Honored at the GRAMMYs on the Hill® Awards
On April 30, the Recording Academy® will host its annual GRAMMYs on the Hill® Awards, Washington's premier annual celebration of music and advocacy, bringing together congressional leaders and music makers to recognize those who have led the fight...

at 12:45
NowVertical Group Announces Amendment to Acrotrend Obligations
NowVertical Group Inc. , ("NOW" or the "Company"), is pleased to announce that Acrotrend Solutions Limited ("Acrotrend") has achieved Adjusted EBITDA of US$2.1 million for the year ended December 31, 2023. In addition, in an effort to further align...

at 11:30
Nanotechnology Market to Surpass USD 53.51 Billion by 2031 | SkyQuest Technology
SkyQuest projects that the nanotechnology market will attain a value of USD 53.51 billion by 2031, with a CAGR of 36.4% over the forecast period (2024-2031). The increasing demand for nanotechnology in medical research fuels the demand. During...

at 10:30
ProStar Announces Stake Center Locating Is Evaluating PointMan
ProStar Holdings Inc., ("ProStar®" or "the Company") , a world leader in Precision Mapping Solutions, is pleased to announce that Stake Center Locating, one of Nation's largest utility locating firms has signed a deal to trial ProStar's flagship...

at 10:25
ExThera Medical Announces Formation of New Business Advisory Board
ExThera Medical, a developer of oncologic and pathogen therapies, today announced the formation of an advisory board consisting of leading experts in business, government affairs/public policy, finance, and emerging technology. The Business Advisory...

More news about Covid-19 virus...


News published on and distributed by: